Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

The head office and logo of Valeant Pharmaceutical are pictured in Montreal on Monday May 27, 2013.

Ryan Remiorz/THE CANADIAN PRESS

Valeant Pharmaceuticals International Inc., the drug maker in a bidding war to purchase Salix Pharmaceuticals Ltd., raised $10.1-billion from the largest junk-bond sale in almost a year.

The notes, boosted from $9.6-billion, were sold in four parts Friday, according to a company statement. The portion with the longest maturity, which also tied for the biggest slice, consisted of $3.25-billion in 6.125 per cent, 10-year bonds that yield 4 percentage points more than comparable Treasuries, according to data compiled by Bloomberg. That's 0.62 percentage point less than the premium paid on all junk bonds, according to a Bank of America Merrill Lynch Index.

Valeant, which agreed last month to pay $158 a share, or $10.1-billion, for Salix, is facing a rival bid from Endo International PLC, which earlier this week offered $175 per share. Valeant said it will redeem the bonds in full if it's unable to complete the purchase by Aug. 20, 2015.

Story continues below advertisement

"Valeant will get the deal for Salix," said Mark McCabe, a credit analyst at KDP Asset Management Inc. "It's a bigger company and has a track record of smoothly integrating acquisitions."

The junk-bond sale is the largest since billionaire Patrick Drahi's Numericable-SFR and Altice SA sold $16.6-billion of debt in April, Bloomberg data show. Valeant is also raising bank loans to fund the purchase, Bloomberg data show.

Biggest Purchase

Excluding Salix, which would be Valeant's biggest purchase, the drug maker has completed $19.2-billion of deals in the past five years, including the acquisition of eye-care company Bausch & Lomb Inc. in 2013, Bloomberg data show.

Valeant was thwarted by Actavis PLC last year in a long-running quest to buy Botox-maker Allergan Inc.

Moody's Investors Service rates Valeant Ba3, three levels below investment grade. Standard & Poor's gives the company an equivalent double-B-minus grade.

Valeant's stock has gained 39 per cent over the past year, nearly quadrupling the 11-per-cent gain of the Standard & Poor's 500 Index, Bloomberg data show.

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies